Gary A. Flynn

Gary Flynn is a seasoned professional in medicinal chemistry with extensive experience in both industry and academia. As Co-Founder of Vibliome Therapeutics, LLC since July 2017, Gary has transitioned into retirement while previously serving as President and Chief Scientific Officer at Vibliome Therapeutics Inc. from September 2017 to July 2021, where Gary focused on developing a kinase inhibitor platform. Gary founded Spacefill Enterprises LLC in December 2007, providing consulting services with an emphasis on structure-based design and the discovery of novel chemo-types. Prior roles include significant contributions at the University of Arizona, Locus Pharmaceuticals, and Aventis Pharmaceuticals, where Gary held positions from Director of Chemistry to Distinguished Scientist. Educationally, Gary holds a PhD in Chemistry from Northwestern University and both BS and MS degrees in Chemistry from Northern Illinois University.